Publications by authors named "Takahiro Yamatake"
Article Synopsis
- The research aimed to evaluate solithromycin's effectiveness, safety, and ability to penetrate tissues in treating ear, nose, and throat infections through three distinct studies.
- The tissue penetration study involved 17 patients who received solithromycin before tissue removal, while the open-label study included 55 patients with various infections and assessed clinical responses post-treatment.
- The non-inferiority study compared solithromycin to high-dose cefcapene-pivoxil in 283 patients with acute rhinosinusitis, focusing on clinical outcomes after treatment.
Introduction: Favipiravir terminates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Accordingly, early administration of favipiravir to SARS-CoV-2-infected coronavirus disease 2019 (COVID-19) patients may be expected to suppress disease progression.
Methods: A randomized double-blind placebo-controlled trial was conducted to demonstrate efficacy of favipiravir in reducing disease progression in patients with mild COVID-19.